Nuvalent doses first patient in Phase 1 trial of HER2-selective inhibitor NVL-330 for NSCLC

Nuvalent, Inc.

Initiated HEROEX-1 Phase 1a/1b trial evaluating NVL-330 in pre-treated patients with HER2-altered NSCLC.
First patient dosed on July 22, 2024; trial will assess safety, tolerability, PK, and preliminary anti-tumor activity.
Trial objectives include determination of recommended Phase 2 dose (RP2D) for NVL-330.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.